Daré Bioscience, Inc. (DARE)
DARENASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.6795
+0.0365 (+5.67%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $13.37m
- P/E
- –
- EPS, last 4 quarters
- $-0.7000
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.6100 to $3.78
- Average volume
- 214.1k
- Previous close
- $0.6430
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $7.33, +978.7% from here
Earnings
next estimate $-0.0900Next report Nov 12, 2026
Sep 2025
+15.2%
Dec 2025
+91.7%
Mar 2026
+39.4%
Jun 2026
+39.4%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $2,000 | $1.02m | $152.0k | $188.0k |
| Gross profit | $2,000 | $728.0k | -$90.0k | -$132.0k |
| Operating income | -$3.67m | -$1.47m | -$3.00m | -$2.97m |
| Net income | -$3.56m | -$1.44m | -$3.00m | -$2.98m |
Last four quarters: revenue $1.37m, margin -804.4%, free cash flow –
News
8 latest- Daré Bioscience Launches CEO Corner Series To Update Investors On Women's Health Pipeline RTTNews · Oct 13, 2026
- Daré Bioscience Highlights 187-Fold Lower Sildenafil Exposure In Phase 1 Study RTTNews · Oct 8, 2026
- Daré Bioscience Reports Phase 1 Sildenafil Cream Data Showing Lower Systemic Exposure RTTNews · Sep 14, 2026
- Why Now On-Demand Conference Spotlights Nine Emerging Biotech And Healthcare Stories RTTNews · Aug 29, 2026
- Daré Bioscience (DARE) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 20, 2026
- Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue EstimatesZacks · Aug 13, 2026
- Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue EstimatesZacks · Aug 12, 2026
- Daré (DARE) Q4 2025 Earnings Call TranscriptThe Motley Fool · May 21, 2026
The company
Dare Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions. Every innovation Dare Bioscience advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Dare Bioscience is working to close critical gaps in care using science that serves her needs. For decades, women have been told to 'wait it out' or 'live with it,' while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions is lagging. Dare Bioscience is working to change that. Learn more at darebioscience.com.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- darebioscience.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.